NYSEHealth CareHealth Care EquipmentS&P SmallCap 600
$20.21
-5.12 (-20.21%)
Close of Nov 06, 2026 · end-of-day data
AORT 8-K filings, explained
Every material Form 8-K Artivion has filed with the SEC since February 15, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Artivion reported third-quarter 2026 revenue of $123.8 million, up 9% from $113.4 million a year earlier, but swung to a GAAP net loss of $7.9 million, or $0.16 per diluted share, from net income of $6.5 million, or $0.13 per diluted share, in the prior-year quarter. Adjusted EBITDA fell 8% to $22.5 million, and the company narrowed its full-year 2026 revenue and adjusted EBITDA guidance ranges.
Q3 2026 revenue of $123.8 million, up 9% on both GAAP and constant currency bases; On-X grew 13% in constant currency.
Q3 2026 GAAP net loss of $(7.9) million, or $(0.16) per diluted share, versus net income of $6.5 million, or $0.13, in Q3 2025.
Adjusted EBITDA declined 8% to $22.5 million from $24.6 million.
FY 2026 revenue guidance narrowed to $484 million to $492 million from $480 million to $496 million; adjusted EBITDA guidance narrowed to $93 million to $98 million from $92 million to $99 million.
Artivion reported second-quarter 2026 revenue of $125.8 million, up 11% from a year earlier, and adjusted EBITDA of $26.4 million, up 7%. The company posted a GAAP net loss of $13.5 million ($0.28 per diluted share), compared with net income of $1.3 million a year earlier, and reiterated its full-year 2026 revenue and adjusted EBITDA guidance. For shareholders, revenue grew while GAAP profit fell, and the filing also reports the completed Endospan acquisition and an FDA approval for the AMDS Hybrid Prosthesis.
Q2 2026 revenue was $125.8 million, up 11% on a GAAP basis and 9% in constant currency versus Q2 2025 ($113.0 million).
Q2 2026 GAAP net loss was $13.5 million ($0.28 per diluted share), versus net income of $1.3 million ($0.03) in Q2 2025; non-GAAP net income was $6.3 million ($0.13 per share), down from $10.7 million ($0.24).
Full-year 2026 guidance was reiterated: revenue of $480 million to $496 million and adjusted EBITDA of $92 million to $99 million.
The company completed its acquisition of Endospan Ltd. in May 2026 and announced U.S. FDA PMA approval of the AMDS Hybrid Prosthesis.
Artivion reported first-quarter 2026 revenue of $116.3 million, up 18% on a GAAP basis from a year earlier, and net income of $1.4 million, or $0.03 per diluted share, compared with a net loss of $0.5 million a year earlier. The company lowered its full-year 2026 revenue and adjusted EBITDA guidance and said it has exercised its option to acquire Endospan, with an expected net purchase price of about $135.0 million to be funded by term loan borrowings and expected to close in the second quarter of 2026.
Q1 2026 revenue $116.3 million, up 18% GAAP and 12% constant currency; net income $1.4 million, or $0.03 per diluted share
2026 revenue guidance cut to $480 million to $496 million from $486 million to $504 million
2026 adjusted EBITDA guidance cut to $100 million to $107 million from $105 million to $110 million
Endospan option exercised May 7, 2026; base price $175.0 million, expected net price about $135.0 million, plus up to $200.0 million contingent consideration
Artivion reported fourth-quarter 2025 revenue of $116.0 million, up from $97.3 million a year earlier, and GAAP net income of $2.4 million, or $0.05 per diluted share, compared with a net loss of $16.5 million in the prior-year quarter. The company also guided to 2026 revenue of $486 million to $504 million and adjusted EBITDA of $105 million to $110 million.
Q4 2025 GAAP revenue was $116.0 million versus $97.3 million in Q4 2024; full-year 2025 revenue was $441.3 million versus $388.5 million.
Q4 2025 GAAP net income was $2.4 million, or $0.05 per diluted share, versus a net loss of $16.5 million, or $0.39 per share, in Q4 2024.
Full-year 2025 adjusted EBITDA was $89.6 million, and the company expects 2026 adjusted EBITDA of $105 million to $110 million.
Artivion reported third-quarter 2025 revenue of $113.4 million, up 18% from $95.8 million a year earlier, and net income of $6.5 million, or $0.13 per diluted share, compared with a net loss of $2.3 million in the prior-year quarter. The company raised the midpoints of its full-year 2025 revenue and adjusted EBITDA guidance, which points to continued growth for shareholders.
Q3 2025 revenue was $113.4 million, up 18% on a GAAP basis and 16% on a constant currency basis
Q3 2025 adjusted EBITDA rose 39% to $24.6 million from $17.7 million; net income was $6.5 million, or $0.13 per diluted share
Full-year 2025 revenue guidance is now $439 million to $445 million, up from $435 million to $443 million; adjusted EBITDA guidance is now $88 million to $91 million, up from $86 million to $91 million
The company refinanced its credit agreement, extending maturity to 2031 and gaining a new $150 million delayed draw term loan facility
Artivion entered into two real estate purchase contracts on September 26, 2025, to buy two Austin, Texas properties for a combined $20.5 million in cash. The buildings at 1300 East Anderson Lane house its On-X manufacturing operation, and the adjacent 1200 property would let the company expand its Austin footprint as capacity needs rise.
1300 East Anderson Lane purchase: $12.05 million cash; about 75,000 square feet of manufacturing, lab, warehouse and office space the company currently leases
1200 property purchase: $8.45 million cash for a building of about 87,000 square feet adjacent to the 1300 property
Feasibility periods of 45 days (1300) and 100 days (1200) allow the company to withdraw; closings expected within 30 days after each period ends
Artivion entered into a Second Amendment to its Credit and Guaranty Agreement on September 12, 2025, with Ares Capital Corporation as administrative agent. The amendment extends the maturity of its existing term loans and revolving credit facility by one year to January 18, 2031, lowers the interest rate margins on those facilities, and adds a new $150.0 million secured delayed draw term loan. For shareholders, the filing shows added borrowing capacity and a longer repayment timeline, but also a new direct financial obligation tied to the company's debt.
Maturity of existing term loans and revolving credit facility extended one year to January 18, 2031
New $150.0 million secured delayed draw term loan available to borrow on or before September 12, 2027, subject to a maximum total net leverage ratio
Proceeds may fund permitted acquisitions, other permitted investments and capital expenditures
Prepayment premium of 1.00% applies to term loan prepayments made before July 18, 2027
Artivion's board appointed Chief Financial Officer Lance A. Berry as Chief Operating Officer, effective August 11, 2025, while he keeps his CFO and Treasurer roles. Chief Medical Officer Marshall S. Stanton will retire effective March 31, 2026, and the company expects him to provide advisory and transition services for up to one year afterward. The filing discloses no financial results, and the changes are leadership and compensation matters.
Lance A. Berry appointed COO by the board on August 6, 2025, effective August 11, 2025, in addition to his CFO and Treasurer roles
Berry's compensation includes a $540,000 base salary, a bonus target of 70% of base salary, and a target equity grant of $2,250,000 starting in 2026
Marshall S. Stanton, Senior Vice President, Clinical Research and Chief Medical Officer, will retire effective March 31, 2026, with no disagreement cited
Stanton is expected to provide strategic advice and transition services for up to one year after his retirement date
Artivion reported second-quarter 2025 revenue of $113.0 million, up 15% from a year earlier, and swung to a GAAP net income of $1.3 million from a net loss of $2.1 million. The company raised the midpoint of its full-year 2025 reported revenue guidance to $435 million to $443 million and its adjusted EBITDA guidance to $86 million to $91 million, and said it retired its $99.5 million of convertible notes due July 1, 2025 through an exchange for common stock.
Q2 2025 revenue was $113.0 million versus $98.0 million in Q2 2024, up 15% on a GAAP basis and 14% in constant currency.
GAAP net income was $1.3 million, or $0.03 per diluted share, compared with a net loss of $2.1 million, or $0.05 per share, a year earlier.
Full-year 2025 reported revenue guidance rose to $435 million to $443 million from $423 million to $435 million; adjusted EBITDA guidance is now $86 million to $91 million.
Adjusted EBITDA rose 33% to $24.8 million in Q2 2025 from $18.6 million in Q2 2024.
Artivion reported first quarter 2025 revenue of $99.0 million, up 2% on a GAAP basis, but swung to a GAAP net loss of $0.5 million, or $(0.01) per share, from net income of $7.5 million a year earlier. The company raised the midpoint of its full year 2025 revenue guidance to $423 to $435 million, while its adjusted EBITDA outlook of $84 to $91 million was unchanged. The quarter was affected by the November 2024 cybersecurity incident, which reduced preservation services revenue by 23%.
Q1 2025 revenue was $99.0 million versus $97.4 million in Q1 2024, up 2% on a GAAP basis and 4% on a constant currency basis.
GAAP net loss was $(0.5) million, or $(0.01) per diluted share; non-GAAP net income was $2.5 million, or $0.06 per diluted share.
Adjusted EBITDA rose 1% to $17.5 million from $17.3 million a year earlier.
Full year 2025 revenue guidance is $423 to $435 million; adjusted EBITDA guidance remains $84 to $91 million.
Artivion reported fourth quarter 2024 revenue of $97.3 million, up 4% on a GAAP basis, and a net loss of $16.5 million, or $(0.39) per share, compared with a net loss of $4.0 million, or $(0.10) per share, a year earlier. For full year 2024, revenue rose 10% to $388.5 million and the net loss narrowed to $13.4 million. The company expects 2025 revenue of $420 million to $435 million and adjusted EBITDA of $84 million to $91 million, and said a late November 2024 cybersecurity incident negatively affected fourth quarter revenue.
Q4 2024 revenue $97.3 million, up 4% GAAP and 3% constant currency versus Q4 2023
Q4 2024 net loss $(16.5) million, or $(0.39) per diluted share, versus $(4.0) million, or $(0.10), in Q4 2023
Full year 2024 revenue $388.5 million, up 10%; adjusted EBITDA $71.3 million, up 32%
2025 outlook: revenue $420 million to $435 million; adjusted EBITDA $84 million to $91 million
Artivion reported third-quarter 2024 results on November 7, 2024. Revenue rose 9% to $95.8 million from $87.9 million a year earlier, and the GAAP net loss narrowed to $2.3 million, or $0.05 per diluted share, from $9.8 million, or $0.24 per share. The company narrowed its full-year 2024 revenue guidance to $389 million to $396 million, with the low end raised from $388 million, and kept its adjusted EBITDA outlook of $69 million to $72 million.
Q3 2024 revenue was $95.8 million, up 9% on a GAAP basis and 10% in constant currency, versus $87.9 million in Q3 2023.
GAAP net loss was $2.3 million ($0.05 per diluted share), compared with a $9.8 million loss ($0.24 per share) a year earlier; non-GAAP net income was $5.0 million ($0.12 per share).
Full-year 2024 revenue guidance narrowed to $389 million to $396 million, from $388 million to $396 million previously.
Adjusted EBITDA rose 28% to $17.7 million in Q3 2024; full-year adjusted EBITDA is still expected at $69 million to $72 million.
Artivion reported second-quarter 2024 revenue of $98.0 million, up 10% from $89.3 million a year earlier, and a net loss of $2.1 million ($0.05 per diluted share), narrower than the $3.4 million loss ($0.08 per share) in the prior-year quarter. The company raised its full-year 2024 revenue and adjusted EBITDA guidance, though the increases at the midpoint are small.
Q2 2024 revenue $98.0 million vs. $89.3 million in Q2 2023, up 10% on both GAAP and constant currency bases
Q2 2024 net loss of $2.1 million ($0.05 per diluted share) vs. net loss of $3.4 million ($0.08 per share) in Q2 2023; non-GAAP net income $2.9 million ($0.07 per share)
Adjusted EBITDA rose 35% to $18.6 million from $13.8 million
FY24 revenue guidance raised to $388 million to $396 million from $386 million to $396 million; adjusted EBITDA guidance raised to $69 million to $72 million from $68 million to $72 million
Artivion amended its 2019 loan and purchase option agreements with Endospan Ltd., a privately held developer of the NEXUS stent graft system. Artivion will provide up to $25 million in additional secured loans, and the option's upfront payment is cut from $250 million to $175 million, or $135 million after loan offset. The company does not expect the amended agreement to have a material impact on its full-year 2024 guidance, and the option takes effect only if Artivion exercises it.
Up to $25 million in new secured loans to Endospan, in tranches of $7 million, $10 million and $8 million; first tranche to be funded as soon as practicable
Loans bear 5% annual interest and are due on the earlier of a third-party acquisition of Endospan or December 31, 2027
Upfront purchase payment reduced from $250 million to $175 million, or $135 million inclusive of loan offset; $100 million minimum earnout eliminated
Company does not anticipate a material impact on full-year 2024 financial guidance
Artivion reported first-quarter 2024 revenue of $97.4 million, up 17% from $83.2 million a year earlier, and net income of $7.5 million, or $0.18 per diluted share, compared with a net loss of $13.5 million a year earlier. The company raised the low end of its full-year 2024 revenue guidance to $386 million to $396 million, while its adjusted EBITDA forecast of $68 million to $72 million was unchanged.
Q1 2024 revenue $97.4 million, up 17% on a GAAP basis and 16% in constant currency
Net income $7.5 million ($0.18 per diluted share) vs. net loss of $13.5 million ($0.33 per share) in Q1 2023; non-GAAP net income $2.6 million ($0.06 per share)
Non-GAAP adjusted EBITDA rose 60% to $17.3 million from $10.8 million
FY2024 revenue guidance $386 million to $396 million (previously $382 million to $396 million); adjusted EBITDA guidance $68 million to $72 million unchanged
Artivion reported fourth-quarter 2023 revenue of $93.7 million, up 18% on a GAAP basis from a year earlier, and full-year revenue of $354.0 million, up 13%. The company swung to a fourth-quarter net loss of $4.0 million, or $0.10 per diluted share, from net income of $2.2 million, or $0.05 per share, a year earlier. It also guided to 2024 revenue of $382 million to $396 million and non-GAAP adjusted EBITDA of $68 million to $72 million.
Q4 2023 revenue was $93.7 million, up 18% GAAP and 15% constant currency from $79.4 million in Q4 2022
Q4 2023 net loss was $4.0 million ($0.10 per diluted share) versus net income of $2.2 million ($0.05) in Q4 2022
Full-year 2023 net loss was $30.7 million ($0.75 per share); non-GAAP adjusted EBITDA rose to $53.8 million
2024 outlook: revenue of $382 million to $396 million (8% to 12% growth) and adjusted EBITDA of $68 million to $72 million
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Artivion filing is on SEC EDGAR ↗. 8-K briefs of other companies →